Syncona founds new gene therapy company
Syncona, the UK life sciences investor, has launched a new gene therapy company, through a £45m series A private fundraising round. The company could be a future candidate for a lucrative biotech listing.
The new firm, Purespring, will be one of the first adeno-associated virus (AAV) gene therapy companies focused on the kidneys.
AAV gene therapy is a method through which an adeno-associated virus is transformed from a naturally occurring virus into a delivery mechanism for gene treatment.Series A financing ...